Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Protein Block Stops Vascular Damage in Diabetes

By BiotechDaily International staff writers
Posted on 24 Jun 2013
A new study demonstrates that the inhibition of a protein activated when blood sugar is raised suppresses accelerated atherosclerosis in diabetic mice.

Researchers at Lund University (Sweden) conducted a study in Streptozotocin (STZ)-induced diabetic in mice to investigate whether Nuclear Factor of Activated T-Cells (NFAT) activation may be a link between diabetes and atherogenesis, by measuring blood monocytes, endothelial activation, and inflammatory markers in the aorta, and proinflammatory cytokines in plasma. The study was initiated following previous studies that showed that hyperglycemia activates the transcription factor NFAT in the arterial wall, inducing the expression of the pro-atherosclerotic protein osteopontin.

The study showed that NFAT activation resulted in 2.2 fold increase in aortic atherosclerosis and enhanced proinflammatory burden. Subsequent in vivo treatment with the NFAT blocker A-285222 for four weeks completely inhibited the diabetes-induced aggravation of atherosclerosis, while having no effect in nondiabetic mice. The STZ-treated mice also exhibited hyperglycemia and higher plasma cholesterol and triglycerides, but these were unaffected by A-285222. In fact, the substance did not affect NFAT in any other cells or organs, ruling out systemic immunosuppression as the mechanism behind reduced atherosclerosis. The study was published in the June 3, 2013, issue of PLOS one.

“That is important. We don’t want to suppress the whole immune system. We also saw that the substance only has an effect when NFAT is active. The plaque formation was only stopped in diabetic mice and not in nondiabetic mice, which had normal blood sugar levels”, said lead author Anna Zetterqvist, MSc. “It appears that there are different mechanisms behind plaque formation caused by diabetes and not caused by diabetes.”

A wealth of epidemiologic evidence demonstrate that hyperglycemia promotes a widespread and aggressive form of atherosclerosis in the coronary arteries, lower extremities, and extracranial carotid arteries of diabetic patients, causing nearly 80% of all deaths and much of their disability. Both diabetes type 1 and type 2 are independent risk factors for myocardial infarction (MI), peripheral vascular disease (PVD), and stroke. In addition, recent studies also show a causal association between elevated glucose levels and increased carotid intima-media thickness, a marker of subclinical atherosclerosis.

Related Links:
Lund University



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.